Evaxion Biotech (EVAX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech A/S, a pioneering AI-Immunology™ vaccine developer, reported progress in its business model and partnerships, alongside announcing its Q2 2024 financial results, showing a strengthened cash position and upcoming clinical milestones. The company anticipates key data readouts and aims to match its 2024 business development income with its cash burn, while navigating a net loss and working on compliance with Nasdaq requirements.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.